secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023488
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity receives Nasdaq delisting notice; July CyPath Lung sales up 72% over prior monthly average
--------------------------------------------------------------------------------

- Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
- Stockholders' equity of $1,439,404 at March 31, 2025 remains below the $2.5M minimum, adding a second delisting basis.
- Company intends to appeal by Aug 14, 2025; delisting scheduled for Aug 18 if appeal not filed.
- July completed tests for CyPath Lung surged 72% over the average of the first six months of 2025.
- Company reaffirms forecast of 3X year-over-year revenue for CyPath Lung; back-to-back record months in June and July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/0001641172-25-023488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer